NewAmsterdam Pharma Co N.V.
NAMSNasdaqHealthcare · Pharmaceutical Preparations · P7 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | |
|---|---|---|---|---|
| Revenue | $22.5M | $45.6M | $14.1M | $102.7M |
| Operating income | −$225.7M | −$176.3M | −$183.0M | −$3.6M |
| Net income | −$203.8M | −$241.6M | −$176.9M | −$22.6M |
| Total assets | $769.3M | $864.6M | $347.1M | $478.5M |
| Total liabilities | $85.9M | $107.1M | $58.7M | $48.4M |
| Equity | $683.4M | $757.5M | $288.4M | $430.1M |
| EPS (diluted) | $-1.72 | $-2.56 | $-2.15 | $-1.19 |
| Shares out. | 109.8M | 89.3M | 82.5M | 36.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1002.9%
- Net margin
- −905.7%
- Return on equity
- −29.8%
- Return on assets
- −26.5%
- Return on capital (ROCE)
- −33.0%
- Liabilities / assets
- 11.2%
- Debt / equity
- 0.13×
- Book value / share
- $6.22
- Revenue growth (YoY)
- −50.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 8.19safe
- Accruals / assets
- −7.3%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 4 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Bcls Ii Investco, LpActivist (13D)May 14, 2026
- Fmr LlcPassive (13G)May 6, 2026
- Viking Global Investors LpPassive (13G)Feb 17, 2026
- Capital World InvestorsPassive (13G)Nov 13, 2025
- Frazier Life Sciences X, L.P.Activist (13D)Nov 4, 2025
- Forbion Capital Fund Iv Cooperatief U.A.Activist (13D)Sep 30, 2025
- Ra Capital Management, L.P.Passive (13G)May 15, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 7.1M | 3.7 | -9.4% |
| Apr 30, 2026 | 7.9M | 8.9 | +2.6% |
| Apr 15, 2026 | 7.7M | 8.7 | -4.5% |
| Mar 31, 2026 | 8.0M | 9.6 | +6.6% |
| Mar 13, 2026 | 7.5M | 7.3 | -1.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 7, 2026
- Director / officer changeApr 24, 2026
- Regulation FD disclosureMar 2, 2026
- Results of operationsFeb 18, 2026
- Results of operations · Regulation FD disclosureJan 9, 2026
- Results of operations · Regulation FD disclosureNov 5, 2025
- Regulation FD disclosureSep 2, 2025
- Regulation FD disclosure · Other material eventAug 18, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.